Catalyst Event
Natera Inc (NTRA) · Other
From KEDI U.S. Medical AI Index (KUSMAI)
3/16/2026, 12:00:00 AM
Announced the publication of two peer-reviewed studies on March 16, 2026, highlighting the clinical utility of its Signatera test in anal and rectal cancers, showing positive results for predicting survival and recurrence.
Korean Translation
2026년 3월 16일, 항문암 및 직장암에서 Signatera 테스트의 임상적 유용성을 강조하는 두 건의 동료 심사 연구 발표. 생존 및 재발 예측에 긍정적인 결과를 보임.
Related Recent Events
Alphabet Inc (GOOGL) · Other
Google I/O 2026 developer conference is scheduled for 2026-05-19. Developer conferences usually have a 1-5% price impact. Updates on AI, Gemini, and Android are expected.
5/19/2026, 12:00:00 AM
Hims & Hers Health Inc (HIMS) · Earnings Release
Q1 2026 earnings release is scheduled for 2026-05-11. Analysts forecast revenue between $600M-$625M and adjusted EBITDA of $35M-$55M. Low importance is estimated as the market typically anticipates scheduled earnings results, which is forecasted.
5/11/2026, 12:00:00 AM
BioNTech SE (BNTX) · Earnings Release
First quarter 2026 earnings results and conference call scheduled.
5/5/2026, 12:00:00 AM
Tempus AI Inc (TEM) · Earnings Release
Q1 2026 earnings release on May 5, 2026, with low importance estimated as the date is unconfirmed, expected.
5/5/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
Q1 2026 earnings release scheduled. Analysts forecast EPS around $7.25-$7.50 estimated. High importance estimated due to the significant weight of earnings reports on stock volatility.
4/30/2026, 12:00:00 AM
AbbVie Inc (ABBV) · Earnings Release
First quarter 2026 earnings release; importance is estimated as Medium because quarterly earnings reports often result in price movements exceeding 5%, scheduled.
4/24/2026, 12:00:00 AM